42182-27-4

Basic information

• Product Name: 2-Amino-4-cyanopyridine
• Synonyms: 4-PYRIDINECARBONITRILE, 2-AMINO-;2-AMINO-4-CYANOPYRIDINE;2-Aminoisonicotinonitrile;4-Cyano-2-pyridinamine;5-AMINO-4-CYANOPYRIDINE;2-Amino-4-pyridinecarbonitrile;2-aminopyridine-4-carbonitrile;2-Amino-4-cyanopyrid
• CAS NO: 42182-27-4
• Molecular Formula: C₆H₅N₃
• Molecular Weight: 119.12
• EINECS: -0
• Product Categories: Pyridines, Pyrimidines, Purines and Pteredines;pharmacetical;Pyridine series;Chemical Amines;Pyridine;Amines;Heterocycles;Pyridines;Heterocycle-Pyridine series
• Mol File: 42182-27-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 146-148°C
• Boiling Point: 297.7 °C at 760 mmHg
• Flash Point: 133.8 °C
• Appearance: /
• Density: 1.23 g/cm³
• Vapor Pressure: 0.00133mmHg at 25°C
• Refractive Index: 1.594
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.93±0.11(Predicted)
• Water Solubility: Slightly soluble in water.
• BRN: 386393
• CAS DataBase Reference: 2-Amino-4-cyanopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4-cyanopyridine(42182-27-4)
• EPA Substance Registry System: 2-Amino-4-cyanopyridine(42182-27-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 20/21/22-36/37/38-41-37/38-22
• Safety Statements: 26-36/37/39-36-39
• RIDADR: 3439
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 42182-27-4(Hazardous Substances Data)

Usage

Chemical Properties

Yellow or pale brown cryst powder

Uses

Different sources of media describe the Uses of 42182-27-4 differently. You can refer to the following data:
1. 2-Amino-4-cyanopyridine is used in the treatment of central nervous system (CNS) disorders and as a mGluR2 antagonist.
2. 2-Amino-4-cyanopyridine is a pyridine derivative as mGluR2 antagonists; used in the treatment of CNS disorders.

InChI:InChI=1/C6H5N3/c7-4-5-1-2-9-6(8)3-5/h1-3H,(H2,8,9)

Upstream product

• 19798-80-2 2-Amino-4-chloropyridine 
• 557-21-1 dicyanozinc 
• 504-29-0 2-aminopyridine 
• 557-21-1 zinc(II) cyanide 
• 84249-14-9 2-amino-4-bromopyridine 
• 737000-78-1 tert-butyl (4-cyanopyridin-2-yl)carbamate 
• 552331-00-7 4-(iodo)pyridin-2-amine 
• 33252-30-1 2-chloro-4-pyridinenitrile 

Downstream Products

• 1608144-25-7 2-amino-2-(5-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)furo[2,3-b]pyridin-2-yl)propane-1,3-diol 
• 94805-51-3 2-hydroxyisonicotinonitrile 
• 1608146-70-8 5-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-3-iodopyridin-2-ol 
• 1608146-72-0 tert-butyl N-(5-{5-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]furo[2,3-b]pyridin-2-yl}-2,2-dimethyl-1,3-dioxan-5-yl)carbamate 
• 1620677-19-1 4-bromo-N-(4-cyanopyridin-2-yl)-3-fluorobenzamide 
• 1620677-18-0 N-(4-cyanopyridin-2-yl)-3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1620677-22-6 N-(4-cyanopyridin-2-yl)-3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1620677-23-7 4-bromo-N-(4-cyanopyridin-2-yl)-3-methoxybenzamide 
• 1620677-21-5 4-bromo-N-(4-cyanopyridin-2-yl)-2-fluorobenzamide 
• 1620677-20-4 N-(4-cyanopyridin-2-yl)-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 38224-41-8 2-(4-bromophenyl)imidazo[1,2-a]pyridine-7-carbonitrile 
• 1612886-86-8 ethyl 2-(2-aminopyridin-4-yl)-4-phenylthiazole-5-carboxylate 
• 1496581-76-0 2-((6-(3,3-difluoropyrrolidin-1-yl)-4-(1-(oxetan-3-yl)piperidin-4-yl)pyridin-2-yl)amino)isonicotinonitrile 
• 1418307-35-3 N-(4-cyanopyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES

Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFRβ kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I) or pharmaceutically acceptable salts thereof. (Formula I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.